Skip to main content
Clinical Trials/ACTRN12611001083987
ACTRN12611001083987
Active, not recruiting
Phase 3

A randomised controlled trial of excisional surgery versus imiquimod 5% cream for nodular and superficial basal cell carcinoma; primary outcome is success (no treatment failure or recurrence) at 3 years.

niversity of Nottingham0 sites500 target enrollmentOctober 19, 2011

Overview

Phase
Phase 3
Intervention
Not specified
Conditions
low risk superficial basal cell carcinoma
Sponsor
niversity of Nottingham
Enrollment
500
Status
Active, not recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
October 19, 2011
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
niversity of Nottingham

Eligibility Criteria

Inclusion Criteria

  • People with low risk superficial or nodular basal cell carcinoma (histologically proven basal cell carcinoma)

Exclusion Criteria

  • Genetic/nevoid conditions e.g. Gorlin's syndrome.
  • Morphoeic (microinfiltrative) trial lesion as diagnosed clinically.
  • Allergy to any of the interventions.
  • Involvement in a trial of another experimental intervention.
  • Life threatening disease.
  • Patients with bleeding disorders.
  • Patients not available for follow up for 3 yrs.
  • Pregnant, intention to become pregnant during treatment phase of the trial, or breastfeeding.

Outcomes

Primary Outcomes

Not specified

Similar Trials